Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Guizhounli Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:603439'
s EV-to-FCF Range Over the Past 10 Years
Min: 1.75 Med: 46.87 Max: 592.18
Current: 29.8
During the past 13 years, the highest EV-to-FCF of Guizhounli Pharmaceutical Co was 592.18. The lowest was 1.75. And the median was 46.87.
SHSE:603439's EV-to-FCF is ranked worse than 58.97% of 563
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs SHSE:603439: 29.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guizhounli Pharmaceutical Co (SHSE:603439) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guizhounli Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Guizhounli Pharmaceutical Co's share price for today is ¥11.41.
Guizhounli Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guizhounli Pharmaceutical Co EV-to-FCF Related Terms
Guizhounli Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's EV-to-FCF falls into.
Guizhounli Pharmaceutical Co's current Enterprise Value is ¥5,159 Mil.
Guizhounli Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥167 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co (SHSE:603439) has a EV-to-FCF of 30.83 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guizhounli Pharmaceutical Co and its competitors. This is 34% below median its historical median of 46.87. Over the past decade, Guizhounli Pharmaceutical Co's EV-to-FCF has ranged from 1.75 to 592.18. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #332 out of 563 companies in the Drug Manufacturers industry, placing it in the top 59%.
Is Guizhounli Pharmaceutical Co's EV-to-FCF too high?
Guizhounli Pharmaceutical Co's current EV-to-FCF of 30.83 is 34% below median its 10-year median of 46.87. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 592.18. The Drug Manufacturers industry median EV-to-FCF is 21.03. Guizhounli Pharmaceutical Co's value of 30.83 is 46.6% above this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #332 out of 563 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #332 out of 563 companies for EV-to-FCF. This places Guizhounli Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 21.03. Guizhounli Pharmaceutical Co's value of 30.83 is 46.6% above this benchmark. Historically, Guizhounli Pharmaceutical Co's own EV-to-FCF has ranged from 1.75 to 592.18 over the past decade. While the company's 10-year median is 46.87 vs. the industry median of 21.03, Guizhounli Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.03, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current EV-to-FCF of 30.83 is 46.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current EV-to-FCF is 30.83, which is 34% below median its own 10-year median of 46.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.41 — trading 22.4% below its estimated fair value. The current EV-to-FCF is 30.83, which is 34% below median its 10-year median of 46.87 and 46.6% above the Drug Manufacturers industry median of 21.03. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current EV-to-FCF is 30.83 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥11.41 is trading 22.4% below its estimated GF Value™ of ¥14.70.
GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603439:
EV-to-FCF: 30.83 (34% below median its 10-year median of 46.87)
GF Value™: ¥14.70 vs. price of ¥11.41 (22.4% below fair value)
Industry Position: 46.6% above the Drug Manufacturers median (#332 of 563)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
